Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$201.66M+231.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Anthony Zook
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,500
- Beta
- 1.75
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.70
Financials
Revenue
$201.66M+231.9%Net Income
$2.24MEBITDA
$18.82M+153.1%Free Cash Flow
$11.74M+52.1%EPS (diluted)
$0.10Shares Outstanding (diluted)
26.17M+67.4%Operating Expenses
$101.65MCash & Debt
$145.54MReturn of Capital
$22.69MRevenue by Segment (annual)
$117.51MDividend per Share
$0.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $727.33M | $-108.03M | $-4.20 |
| 2024 | $660.57M | $-78.73M | $-3.10 |
| 2023 | $591.64M | $-87.97M | $-3.50 |
| 2022 | $509.73M | $-144.25M | $-5.80 |
| 2021 | $484.33M | $-8.35M | $-0.35 |
| 2020 | $444.45M | $4.17M | $0.19 |
| 2019 | $408.83M | $8.01M | $0.40 |
| 2018 | $276.74M | $2.64M | $0.14 |
| 2017 | $240.25M | $-396.0K | $-0.03 |
| 2016 | $244.08M | $-6.14M | $-0.40 |
| 2015 | $99.80M | $-2.54M | $-0.21 |
| 2014 | $87.07M | $1.13M | $0.10 |
| 2013 | $66.47M | $2.03M | $0.20 |
| 2012 | $59.87M | $65.0K | $0.01 |
Valuation
NEOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·8d ago·Negative
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.
View source ↗ - Newsmarketbeat.com·15d ago·Negative
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F.
View source ↗ - Newsglobenewswire.com·27d ago·Positive
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases.
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
View source ↗ - Newszacks.com·42d ago·Positive
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newsnewsfilecorp.com·55d ago·Neutral
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Neo Performance Materials Q2 Earnings Call Highlights Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $0.06 per share
Typical surprise +41.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.05 vs $0.03beat
- Tue, Apr 28$0.01 vs $0.01beat
- Tue, Feb 17$0.06 vs $0.04beat
- Tue, Oct 28$0.03 vs $0.02beat
- Tue, Jul 29$0.03 vs $0.03beat
- Tue, Apr 29$-0.08 vs $-0.02miss
Estimates and results for NEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NEO officers and directors.
- Bought
- —
- Sold
- $717k
0 trades
4 trades
- Aunan Greg Dsold
- Tetrault Lynn A.sold
- Tetrault Lynn A.sold
- Stone Warrensold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (35d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (33d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 6, 2025 (30d later)Buy$1,001 - $15,000
- Deborah K. Rosshouse · NC02 · disclosed Jan 8, 2022 (9d later)Buy$15,001 - $50,000
- Bob Gibbshouse · OH07 · disclosed Nov 14, 2021 (5d later)Sell$1,001 - $15,000
- Dwight Evanshouse · PA03 · disclosed Apr 23, 2020 (52d later)Buy$1,001 - $15,000
- Bob Gibbshouse · OH07 · disclosed Dec 20, 2019 (1d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.